Welcome to our dedicated page for Evogene news (Ticker: EVGN), a resource for investors and traders seeking the latest updates and insights on Evogene stock.
Evogene Ltd. reports developments as a computational chemistry company focused on generative design of small molecules for pharmaceutical and agricultural applications. Its recurring updates center on ChemPass AI™, a proprietary generative AI platform used to explore chemical space and optimize small-molecule candidates across multiple parameters.
Company news also covers financial results, strategic refocusing around ChemPass AI™, collaborations in drug discovery and ag-chemical development, and subsidiary activity. Reported subsidiary themes include Casterra's castor seed varieties and castor farming systems for bio-based industries, AgPlenus work on novel herbicides and fungicides, Biomica microbiome-based therapeutics, and Nasdaq listing-compliance matters for EVGN ordinary shares.
Evogene (NASDAQ:EVGN), a computational chemistry company focused on generative AI design of small molecules for pharma and agriculture, will present at the 24th Schrödinger European User Group Meeting in Munich, Germany, held May 19–21, 2026.
Head of Algorithms Dr. Roberto Olender will speak in the Small Molecules track session “Project Advancements Through Custom Computational Models” on May 20, 2026, 11:00 AM–12:30 PM CEST, sharing progress on a multi-objective GenAI foundation model for de novo molecule design.
Evogene (NASDAQ: EVGN) will release its Q1 2026 financial results on Wednesday, May 20, 2026. Management will host a live Zoom conference call the same day at 9:00 AM ET (4:00 PM Israel). Registration is required: https://www.veidan-conferencing.com/evogene. A replay will be posted on the company's website a few days after the call.
Evogene (NASDAQ: EVGN) received a Nasdaq notice for noncompliance with the $1.00 minimum bid price rule after its closing bid remained below $1.00 for 30 consecutive business days.
The company has a 180-calendar-day cure period ending September 28, 2026 to regain compliance (10 consecutive business days at $1.00+). Trading will continue on Nasdaq during the cure period, and Evogene may consider options including a reverse stock split if needed.
Evogene (NASDAQ: EVGN) subsidiary Casterra reported successful commercial field trials across 74 hectares in Bahia, Brazil, showing mechanized, low-input castor farming can be economically viable for castor oil feedstock. Trials included 64 hectares rainfed, 10 hectares irrigated, and recorded 382 mm rainfall.
Casterra plans a 2026 push via a local subsidiary, strategic partnerships with castor oil producers, and expanded trials across multiple Brazilian states to support castor as a scalable biofuel feedstock.
Evogene (NASDAQ: EVGN) will present pharma discovery achievements at BIO-Europe Spring 2026 in Lisbon, March 23–25, 2026. Evogene delegates Dr. Gabi Tarcic and Dr. Olga Nissan will deliver an oral presentation on March 24, 2026, 15:30 WET and are available for one-on-one meetings.
The presentation will highlight AI-driven small-molecule discovery and the company’s ChemPass AI™ platform enabling collaborative drug discovery with pharma and biotech partners.
Evogene (NASDAQ: EVGN) reported fourth-quarter and full-year 2025 results and outlined a strategic refocus on its proprietary ChemPass AI™ small‑molecule engine for pharma and agriculture. 2025 highlights include operating expenses reduced to ~$13.8M, consolidated cash of ~$13.0M, 2025 revenue of ~$3.9M, and a $6.4M gain from the Lavie Bio asset sale.
The company recorded a 2025 operating loss of ~$14.0M and net loss of ~$7.8M, implemented divestitures and restructurings, recognized a $2.2M inventory impairment at Casterra, and secured ~ $3.4M gross proceeds from a February 2026 warrant exercise inducement.
Evogene (Nasdaq: EVGN) outlined a 2025 strategic transformation to focus on its proprietary ChemPass AI™ engine and two markets: human health and agriculture. The company divested non-core assets, resized the organization, and said ChemPass AI™ leverages a 38‑billion‑molecule foundation model and partnerships including Google Cloud, Bayer, and Corteva.
Evogene reported partnered drug discovery progress, four disclosed collaborations, AgPlenus agricultural programs, and completed divestments of Lavie Bio and a license of Biomica's BMC128.
Evogene (NASDAQ: EVGN) will release its fourth quarter and full year 2025 financial results on Thursday, March 5, 2026. Management will discuss results in a Zoom conference call the same day at 9:00 AM ET (4:00 PM Israel time).
Investors must register in advance to attend and the full webcast will be posted on the company's website a few days after the call. Registration link: https://www.veidan-conferencing.com/evogene.
Evogene (Nasdaq: EVGN) announced a collaboration with Dr. Mark Adams' group at Queensland University of Technology on Feb 17, 2026 to accelerate AI-driven discovery of small-molecule inhibitors targeting a newly identified enzymatic detoxification pathway that drives Cisplatin resistance in non-small cell lung cancer (NSCLC).
The partnership combines Evogene's ChemPass AI™ generative design platform with QUT's biological insights to generate and iteratively refine drug-like leads aimed at restoring chemotherapy and targeted-therapy sensitivity.
Evogene (Nasdaq: EVGN), Systasy Bioscience and LMU University Hospital Munich announced a collaborative program on Feb. 11, 2026 to develop novel therapies for neutrophil-driven hyper-inflammatory diseases, including IBD. The effort is supported by a pan-European EUREKA grant and includes participation from the Weizmann Institute.
Evogene will lead small-molecule discovery using its ChemPass AI™; Systasy will apply its PathwayProfiler DNA barcoding assays; LMU will validate leads in human stem cell–derived neutrophil models and advance biomarkers and translational plans.